- Home
- RMCF vs IMRN Comparison
RMCF vs IMRN Comparison
Compare RMCF & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- IMRN
- Stock Information
- Founded
- RMCF 1981
- IMRN 1994
- Country
- RMCF United States
- IMRN Australia
- Employees
- RMCF N/A
- IMRN N/A
- Industry
- RMCF Specialty Foods
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- IMRN Health Care
- Exchange
- RMCF Nasdaq
- IMRN Nasdaq
- Market Cap
- RMCF 14.3M
- IMRN 15.0M
- IPO Year
- RMCF N/A
- IMRN N/A
- Fundamental
- Price
- RMCF $2.66
- IMRN $2.00
- Analyst Decision
- RMCF
- IMRN Strong Buy
- Analyst Count
- RMCF 0
- IMRN 1
- Target Price
- RMCF N/A
- IMRN $5.00
- AVG Volume (30 Days)
- RMCF 94.5K
- IMRN 6.1K
- Earning Date
- RMCF 01-08-2025
- IMRN 11-26-2024
- Dividend Yield
- RMCF N/A
- IMRN N/A
- EPS Growth
- RMCF N/A
- IMRN N/A
- EPS
- RMCF N/A
- IMRN N/A
- Revenue
- RMCF $27,743,687.00
- IMRN $3,271,194.00
- Revenue This Year
- RMCF N/A
- IMRN N/A
- Revenue Next Year
- RMCF N/A
- IMRN N/A
- P/E Ratio
- RMCF N/A
- IMRN N/A
- Revenue Growth
- RMCF N/A
- IMRN 171.67
- 52 Week Low
- RMCF $1.50
- IMRN $1.59
- 52 Week High
- RMCF $5.15
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- RMCF 57.00
- IMRN 48.20
- Support Level
- RMCF $2.42
- IMRN $1.73
- Resistance Level
- RMCF $2.70
- IMRN $1.99
- Average True Range (ATR)
- RMCF 0.18
- IMRN 0.11
- MACD
- RMCF -0.03
- IMRN 0.03
- Stochastic Oscillator
- RMCF 27.91
- IMRN 70.82
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.